企業プロフィール
MDxHealth 株価・ニュース・カタリスト
- ティッカー:
- MDXH
- 取引所:
- NASDAQ
- セクター:
- MedTech
- 所在地:
- Belgium and listed in the U
株価パフォーマンス
0.86 USD (+5.89%)
終値
最終更新: 2026年8月17日
32.9M USD
時価総額
株価変動の要因
As of Aug 17, 2026, MDXH closed up 5.89% at $0.8556. No new same-company headline was identified in the current news window.
企業概要
Precision Urologic Diagnostics
MDxHealth provides molecular tests that support diagnosis, risk assessment, and treatment decisions in prostate cancer and other urologic diseases.
Prostate Cancer Menu
The company’s portfolio spans pre-biopsy risk assessment, tissue-based prognostic testing, and post-treatment monitoring, using genomic, epigenomic, and exosomal technologies.
ExoDx Integration
The acquired ExoDx urine-based prostate test broadens the diagnostic menu and is being integrated into MDxHealth’s laboratory, sales, and reimbursement infrastructure.
Portfolio Refocus
MDxHealth is exiting the Resolve UTI business to concentrate investment on prostate cancer and related urologic oncology opportunities.
今後のカタリスト
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。